Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03337074
Other study ID # 182833
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 8, 2017
Est. completion date April 30, 2020

Study information

Verified date July 2019
Source Guy's and St Thomas' NHS Foundation Trust
Contact Saraid McIlvride
Phone 02078486202
Email saraid.a.mcilvride@kcl.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

For some years investigators have known that the health of fathers at the time their baby is conceived has an influence on the health of their child in the future. Many studies looking at this effect have investigated fathers with obesity and other metabolic disorders. These disorders can alter the risk of obesity and diabetes in the children of these men. More recently, studies have been undertaken to establish the mechanism by which this risk is inherited by the children. Studies of sperm have identified that changes in the structure and function of the sperm play a role.

Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis (PBC) are included in a group of cholestatic liver disorders that are associated with elevated levels of bile acids in the blood (cholestasis). A previous study has established that children born to women who have cholestasis during pregnancy are at an increased risk of obesity later in life. Our study will investigate whether there is a similar effect on the health of children if their father has cholestasis.

The study has 2 arms, the Sperm Epigenome arm and the Outcomes arm.

In the Sperm Epigenome arm of the study, the structure and function of sperm from men with PSC, PBC and other cholestatic liver disorders will be investigated and compared to the structure and function of sperm from healthy men.

In the Outcomes arm of the study, basic health parameters of fathers who had PSC, PBC or another cholestatic liver disease either before or after their child was conceived will be studied. Basic health parameters will also be studied in their child when the child is between 16 and 25 years of age.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date April 30, 2020
Est. primary completion date April 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years and older
Eligibility Sperm Epigenome Arm:

Cholestatic men

Inclusion Criteria:

- Men who have a diagnosis of a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis.

- Me who are able and willing to give informed consent.

Exclusion Criteria:

- Men who have a history of diabetes or obesity.

- Men who have gallstones, cancer or other acute cholestatic pathology.

- Men who have a history of alcohol excess or drug abuse.

- Men who smoke.

- Men who have blood-borne viruses e.g. HIV or hepatitis.

- Men unable or unwilling to give informed consent

Healthy men

Inclusion Criteria:

- Men who have no history of cholestasis, liver disease, diabetes or obesity.

- Me who are able and willing to give informed consent.

Exclusion Criteria:

- Men who have a history of cholestasis or liver disease.

- Men who have a history of diabetes or obesity.

- Men who have a history of alcohol excess or drug abuse.

- Men who smoke.

- Men who have blood-borne viruses e.g. HIV or hepatitis.

- Men undergoing fertility treatment due to male factor.

- Men unable or unwilling to give informed consent

Outcomes Arm:

Fathers

Inclusion Criteria:

- Fathers with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis.

- Fathers with cholestatic liver condition whose children are between 16 years - 25 years of age.

- Fathers with cholestatic liver condition who are able and willing to give informed consent.

Exclusion Criteria:

- Fathers with a history of diabetes or obesity at the time of conception of their child.

- Fathers with a history of alcohol excess or drug-abuse at the time of conception of their child.

- Fathers who smoked at the time of conception of their child.

- Fathers with blood-borne viruses e.g. HIV and hepatitis at the time of conception of their child.

- Fathers unable or unwilling to give informed consent.

Children of cholestatic fathers

Inclusion Criteria:

- Adolescents / young adults (between 16 - 25 years of age) whose fathers have a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis or Primary Biliary Cholangitis.

- Adolescents /young adults born from an uncomplicated singleton pregnancy.

- Adolescents /young adults who are able and willing to give informed consent.

Exclusion Criteria:

- Adolescents / young adults who were born as a result of multi-fetal pregnancy.

- Adolescents / young adults with a history of alcohol excess or drug-abuse.

- Adolescents / young adults who are under 16 years of age, or over 25 years of age.

- Adolescents / young adults with blood-borne viruses e.g. HIV and hepatitis.

- Adolescents / young adults who are unable or unwilling to give informed consent.

Study Design


Intervention

Other:
Questionnaire, semen sample, fasting blood sample
Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.
Questionnaire
Participants are asked to complete a questionnaire.
Questionnaire, fasting blood sample
Participants are asked to complete a questionnaire and provide a fasting blood sample.

Locations

Country Name City State
United Kingdom Assisted Conception Unit, Guy's Hospital London
United Kingdom King's College Hospital London

Sponsors (2)

Lead Sponsor Collaborator
Guy's and St Thomas' NHS Foundation Trust King's College Hospital NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Impact of male cholestasis on DNA methylation patterns in sperm 01/04/2018
Primary Impact of male cholestasis on small RNA content in sperm 01/04/2018
Primary Impact of male cholestasis on sperm histone retention 01/04/2018
Primary Impact of paternal cholestasis on the BMI, hip and waist girth of their adolescent / young adult children 01/04/2018
Primary Impact of paternal cholestasis on the general health of their adolescent / young adult children The prevalence of heart, lung, diabetes, thyroid, kidney or liver disease in children of fathers with cholestasis will be investigated 01/04/2018
Secondary Impact of male cholestasis on seminal fluid composition. 01/04/2018
See also
  Status Clinical Trial Phase
Completed NCT02239211 - A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Phase 2
Withdrawn NCT03216876 - A Study Of Ursolic Acid For Primary Sclerosing Cholangitis Phase 1
Recruiting NCT02605213 - Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Phase 4
Recruiting NCT01688024 - Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis Phase 2
Completed NCT03041662 - Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
Completed NCT05866809 - Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis Phase 2
Recruiting NCT05618145 - National Database on Primary Sclerosing Cholangitis (PSC)
Active, not recruiting NCT02446665 - Disease Status in Primary Sclerosing Cholangitis by Elastography N/A
Completed NCT02247934 - Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC) N/A
Completed NCT01088607 - Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis Phase 1
Terminated NCT01142323 - Pilot Study of Fenofibrate for PSC Phase 1/Phase 2
Terminated NCT04060147 - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis Phase 1
Recruiting NCT04133792 - Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC) Phase 3
Active, not recruiting NCT04595825 - CM-101 in PSC Patients -The SPRING Study Phase 2
Recruiting NCT03183570 - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT Early Phase 1
Completed NCT02943460 - Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Phase 2
Completed NCT00951327 - Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP) N/A
Completed NCT04024813 - A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC Phase 2
Recruiting NCT05912387 - Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study Early Phase 1
Completed NCT02884557 - NKT Role in the Regulation of the Inflammatory Bowel Disease N/A